Gastroduodenal safety of Nimesulid (Nimesil, Berlin Chemie) in rheumatic patients with history of ulcer
https://doi.org/10.14412/1995-4484-2003-1132
Abstract
Objective. To assess safety of nimesulid in rheumatic pts with history of ulcer or multiple erosions (ME) of stomach and/or duodenal mucosa. Methods. 42 pts with rheumatic diseases aged 22-73 years were included. AH had gastric or duodenal ulcers or ME (n>10) connected with NSAID treatment and confirmed by endoscopy no more than 6 months before the beginning of the study. Pts were included after healing of ulcers and erosions. The pts were randomized to receive Nimesulid 200 mg/day (group 1) or Diclofenac suppositoria 100 mg/day + ranitidine 150 mg/day (group 2). Esophagogastroduodenoscopy was performed before and 12 weeks after the beginning of treatment. Results. Relapse of stomach ulcer was observed in I pts of group 1 (5,6%). Relapse of NSAID-induced ulcers and ME was noted in 6 pts of group 2 (33,3%): in 4 cases stomach ulcers, in 1 case stomach ME, in 1 case duodenal ulcer (p=0,0424). Presence of gastralgias and dyspepsia was noted in 36,8% pts of group 1 and in 20% pts of group 2 (p=0,0539). In 1 pts of group 2 gastralgias were the reason for premature endoscopy. Conclusion. Nimesil (Nimesulid) can be considered as a more safe drug than classical NSAIDs with smaller risk of serious gastroduodenal complications development in rheumatic pts with ulcer history. The results of the study allow to recommend Nimesulid as a drug of choice for treatment of pts with history of NSAID-induced gastropathy.
References
1. <div><p>Насонов Е.Л. Специфические ингибиторы циклоокси- геназы-2 и воспаление: перспективы применения препарата целебрекс Росс, ревматол., 1999, 4, 2-11</p><p>Насонов Е.Л., Каратеев А.Е. Поражения желудка, связанные с приемом нестероидных противовоспалительных препаратов (Часть 1). Клин, мед., 2000, 3, 4-10; (Часть 2) Клин, мед., 2000, 4, 4-9.</p><p>Цветкова Е.С. Мовалис при остеоартрозе Тер. архив, 1999, 11, 48-50</p><p>Hawkey С., Kahan A, Steinbruck К. et al. Gastrointestinal tolerability of meloxicam compared diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br.J. Rheumat., 1998, 37(9), 1142</p><p>Graham D.Y. Agrawal N.M., Campbell D.R. et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter. active- and placebo-controlled study of misoprostol vs lansoprazole. Arch, intern, med., 2002, 162, 1/28, 169175</p><p>Silverstein F.E., Faich G, Goldstein J.L. et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoartritis and rheumatoid arthritis. The CLASS study: A randomised controlled trial. JAMA, 2000, 284, 10, 1247-1255</p><p>Steen K.S.S., Lems W.F., Aertsen J. et al. Incidence of clinically manifest ulcers and their complication in patients with rheumatoid arthritis. Ann. Rheum. Dis,. 2001, 60, 443-447</p></div><br />
Review
For citations:
Karateyev A.E., Karateyev D.E., Nassonov E.L. Gastroduodenal safety of Nimesulid (Nimesil, Berlin Chemie) in rheumatic patients with history of ulcer. Rheumatology Science and Practice. 2003;41(1):36-39. (In Russ.) https://doi.org/10.14412/1995-4484-2003-1132
Views:
3639
Email this article 